New hope for tough ovarian cancer: first human trial of MEN2501 begins
NCT ID NCT07226427
First seen Nov 10, 2025 · Last updated May 13, 2026 · Updated 22 times
Summary
This early-stage trial tests a new drug called MEN2501 in about 100 adults with ovarian cancer that has stopped responding to platinum-based chemotherapy. The main goals are to find a safe dose and check for side effects. Researchers will also watch for any signs that the drug shrinks tumors or slows the cancer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PLATINUM-RESISTANT OVARIAN CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
NEXT Virginia
RECRUITINGFairfax, Virginia, 22031, United States
Conditions
Explore the condition pages connected to this study.